Munich Re suffers P&C Re margin slide in '23 on ‘claims uncertainty’
Munich Re suffered a moderate slide in P&C reinsurance margins in 2023, citing “claims uncertainty” sufficient to offset lower than planned nat cat and other drivers.
The P&C reinsurance combined ratio rose 2.0 percentage points to 85.2%, but management assured it could push the figure back down towards the 82% mark for 2024.
Major losses proved “slightly better than expected,” but the impact, together with a positive boost from IFRS17 discounted was "more than offset by “prudent reflection of claims uncertainty in basic losses,” management said.
Major-loss expenditure of €3.3 billion, including a burst in Q4, accounted for 12.6 combined ratio points, below the 14 points budgeted and down from 15.4 points in 2022 which had been boosted by Hurricane Ian.
P&C reinsurance revenues grew nearly 7% to nearly €27.1 billion, with management citing “significant growth in nat cat and global specialty insurance, taking advantage of attractive market conditions.”
Life and health reinsurance compensated with a 38% increase in its FY total technical result to €1.43 billion to beat an adjusted target of €1.4 billion. Segment insurance revenues declined on currency translation effects.
Munich Re’s primary insurance group ERGO increased its net contribution 26%, including a major recovery in Q4.
Despite an 80% increase in investment results and the profit gains in life reinsurance and Ergo primary, Munich Re couldn’t scrounge enough to offset the reduced take in P&C reinsurance. A full-year net profit of €4.6 billion was down 13% year on year to fractionally beat forecasts which had been revised up by the group in October.
Munich Re is aiming to generate a net result of €5 billion in 2024 on a reduced top-line gain in re/insurance revenue to €59 billion.
Did you get value from this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Elliot Field at efield@newtonmedia.co.uk or Adrian Tapping at atapping@newtonmedia.co.uk